Somalogic, Inc.

53 articles with Somalogic, Inc.

• SomaLogic Announces Preliminary Revenue for Full Year 2021 Above Guidance Range Presenting at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 8:15 a.m. Eastern Time

  1/11/2022

  SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced preliminary, unaudited revenue expectations for the year ending December 31st , 2021.

• SomaLogic Announces Appointment of Adam Taich as Chief Business Officer

  1/10/2022

  SomaLogic, a leader in data-driven proteomics technology, announced that Adam Taich has joined the company as the Chief Business Officer.

• 

  Top Life Sciences Startups to Watch in 2022

  1/6/2022

  BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.

• Illumina Enters Co-Development Partnership with SomaLogic

  1/5/2022

  Illumina, Inc. announced it has entered into a definitive co-development agreement with SomaLogic to bring the SomaScan® Proteomics Assay onto Illumina's current and future high throughput next-generation sequencing platforms.

• SomaLogic announces exclusive partnership with Illumina to develop sequencing-based proteomic solutions

  1/5/2022

  SomaLogic, a leader in data-driven proteomics technology, announced a worldwide strategic collaboration with Illumina, a global next-generation sequencing technology leader.

• SomaLogic to Participate in the 40th Annual J.P. Morgan Healthcare Conference

  12/30/2021

  SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that the company will be participating in the upcoming 40th Annual J.P. Morgan Healthcare Conference.

• 

  Giving Thanks for Scientific Advances and COVID-19 Relief

  11/25/2021

  With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened this year. And there are many!

• SomaLogic Reports Third Quarter 2021 Financial Results

  11/15/2021

  SomaLogic, Inc., a leader in AI-data driven proteomics technology, today reported financial results for the quarter ended September 30, 2021.

• SomaLogic to Present at the Stifel 2021 Virtual Healthcare Conference

  11/3/2021

  SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that the company will be participating in the upcoming Stifel 2021 Virtual Healthcare Conference.

• SomaLogic to Announce Third Quarter 2021 Financial Results

  10/28/2021

  SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that it will report financial results for the third quarter 2021 before the market opens on Monday, November 15, 2021

• SomaLogic Announces Upcoming Conference Participation and Analyst Meeting

  9/22/2021

  SomaLogic, Inc., a leader in AI-data driven proteomics technology, today is announcing upcoming conference participation in addition to its analyst meeting.

• SomaLogic Announces Registration Statement Declared Effective and Reports 176% Y/Y Second Quarter and 187% First Half of 2021 Revenue Growth

  8/16/2021

  CM Life Sciences II today announced that the registration statement for their business combination has been declared effective by the US Securities Exchange Commission (“SEC” )

• Ixaka and SomaLogic Enter Research Collaboration to Develop Bispecific Agents for Oncology

  6/29/2021

  Ixaka Ltd and SomaLogic announce a research collaboration to support the development of aptamer-based bispecific therapeutics.

• 

  Biopharmas Ink Strategic Partnerships for Research, Treating Major Diseases

  6/29/2021

  ​Three partnerships were signed today between biopharmaceutical and therapeutics companies in a bid to develop treatment for major diseases with high mortality rates. 

• SomaLogic, Leading AI-Data Driven Proteomics Platform for Advanced Research and Clinical Applications, to Combine with CM Life Sciences II, to Drive Growth and Expand Technology Platform

  3/29/2021

  SomaLogic, a global leader in proteomics technology, powered by a proprietary platform, the largest clinical proteomic database and next generation artificial intelligence and machine learning, and CM Life Sciences II (NASDAQ: CMIIU), a special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, today announced that they have entered into a definitive business combination agreement.

• Agilent and SomaLogic Sign Agreement for Supply of Custom Microarrays

  4/30/2019

  Use of Agilent’s custom microarrays in the SOMAscan® assay will help drive biomarker discovery efforts as well as novel diagnostics and accelerated pharmaceutical development

• 

  BioSpace Movers and Shakers: April 26

  4/26/2019

  Companies strengthen leadership teams with C-suite and boards of directors appointments, with new hires at Sandoz, Mission Bio, SkinBio, Epic Sciences, and more.

• SomaLogic announces new collaboration with Janssen Research & Development

  4/11/2019

  Companies to share proteomic and clinical data to drive new drug discovery and development, and precision health management

• SomaLogic to Present at 37th Annual J. P. Morgan Healthcare Conference

  1/2/2019

  Dr. Smythe's presentation, which is included in the Conference's "Emerging Markets Track," is scheduled for Wednesday, January 9, 2019 at 3:00 p.m. Pacific Time.

• deCODE Genetics, An Amgen Subsidiary, And SomaLogic Announce Collaboration To Perform Large-Scale Protein Analysis Of Up To 40,000 Human Samples

  12/13/2018

  Largest-ever Protein Measurement Study Enhances deCODE's Efforts in Basic Research, Drug Discovery and Novel Protein-based Diagnostics